Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins

Statistics in Medicine

Volumn 29, Issue 10, 2010, Pages 1127-1136

  Vittinghoff, Eric ^a   McCulloch, Charles E ^a   Woob, Claudine ^b   Cummings, Steven R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

G computation; Long term effects; Missing at random; Placebo controlled trials

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; SIMULATION; STATISTICAL ANALYSIS; VIRTUAL TWIN;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951613673     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3870     Document Type: Article

References (22)

1. Silverman SL, Cummings SR, Watts NB. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society of Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). Journal of Bone Mineral Research 2008; 23:159-165. DOI: 10.1359/jbmr.070905.
2. Pedersen TR, Wilhemsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology 2000; 86:257-262. (Pubitemid 30462217)
3. Cuzick J, Forbes JF, Cawthorn S, Hamed H, Holli K, Howell A. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized ITIS-I trial. Journal of the National Cancer Institute 2007; 99:272-282. DOI: 10.1093/jnci/djk049. (Pubitemid 47073490)
4. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute 2007; 99:283-290. DOI: 10.1093/jnci/djk050. (Pubitemid 47073491)
5. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Annals of Internal Medicine 1996; 124:548-566.
6. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newly LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). Journal of the American Medical Association 2002; 288:49-57. (Pubitemid 34705518)
7. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE Study extension. Circulation 2005; 112:1339-1346.
8. Tonino RP, Meunier PJ, Emkey R, Rodriguez JA, Menkes C-J, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism 2000; 85:3109-3115.
9. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology 2006; 55:598-696. (Pubitemid 44436647)
10. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European Neuropsychopharmacology 1998; 8:67-75.
11. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Movement Disorders 2001; 16:135-139. (Pubitemid 36041128)
12. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clinical Therapeutics 2003; 25:1765-1782. (Pubitemid 36801947)
13. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months. Archives of Neurology 2004; 61:252-256.
14. Bone HG, Hosking D, Devogalaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine 2004; 350:1189-1199. (Pubitemid 38339363)
15. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment. Journal of the American Medical Association 2006; 296:2927-2938.
16. Ensrud KE, Barrett-Connor E, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MA, Torner JC, Lombardi A, Black DM. Randomized trial of effect of Alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension. Journal of Bone and Mineral Research 2004; 19:1259-1269. (Pubitemid 41094366)
17. Robins JM, Greenland S, Hu F-C. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. Journal of the American Statistical Association 1999; 94:687-700.
18. Little RJA, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annual Review of Public Health 2000; 21:121-145.
19. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the fracture intervention trial. Osteoporosis International 1993; 3:S29-S39.
20. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of the effect of Alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541. (Pubitemid 26411651)
21. Cummings SR, Black DB, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubins SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of Alendronate on risk of fracture in women with low bone density but without vertebral fractures. Journal of the American Medical Association 1998; 280:2077-2082. (Pubitemid 28389832)
22. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR. Fracture risk reduction with Alendronate in women with osteroporosis: the Fracture Intervention Trial. Journal of Clinical Endocrinology and Metabolism 2000; 85:4118-4124. (Pubitemid 32055362)